# Monopar Therapeutics: financial statements, quarterly

MNPR · Nasdaq · CIK 1645469 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mnpr.md) · [Financials](/companies/mnpr/financials.md) · [Filings](/companies/mnpr/filings.md) · [Insiders](/companies/mnpr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mnpr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001437749-26-016982.md) | [0.0 d](/filings/0001437749-26-027164.md) |
| Research and development | $m | [1.3](/filings/0001437749-24-034048.md) | [1.0 d](/filings/0001437749-25-009979.md) | [1.0](/filings/0001437749-25-016263.md) | [1.1](/filings/0001437749-25-026042.md) | [1.0](/filings/0001437749-25-034617.md) | [9.9 d](/filings/0001437749-26-010025.md) | [1.6](/filings/0001437749-26-016982.md) | [1.7](/filings/0001437749-26-027164.md) | [2.6](/filings/0001437749-25-034617.md) | [3.9 d](/filings/0001437749-26-010025.md) | [3.5](/filings/0001437749-26-016982.md) | [4.8](/filings/0001437749-26-027164.md) |
| Operating income | $m | [(2.1)](/filings/0001437749-24-034048.md) | [(1.9) d](/filings/0001437749-25-009979.md) | [(1.7)](/filings/0001437749-25-016263.md) | [(1.8)](/filings/0001437749-25-026042.md) | [(1.6)](/filings/0001437749-25-034617.md) | [(11.1) d](/filings/0001437749-26-010025.md) | [(3.2)](/filings/0001437749-26-016982.md) | [(3.2)](/filings/0001437749-26-027164.md) | [(4.1)](/filings/0001437749-25-034617.md) | [(6.2) d](/filings/0001437749-26-010025.md) | [(5.2)](/filings/0001437749-26-016982.md) | [(6.6)](/filings/0001437749-26-027164.md) |
| Net income | $m | [(2.0)](/filings/0001437749-24-034048.md) | [(1.8) d](/filings/0001437749-25-009979.md) | [(1.6)](/filings/0001437749-25-034617.md) | [(1.7)](/filings/0001437749-25-034617.md) | [(1.3)](/filings/0001437749-25-034617.md) | [(10.9) d](/filings/0001437749-26-010025.md) | [(2.6)](/filings/0001437749-26-027164.md) | [(2.5)](/filings/0001437749-26-027164.md) | [(3.4)](/filings/0001437749-25-034617.md) | [(5.2) d](/filings/0001437749-26-010025.md) | [(3.9)](/filings/0001437749-26-027164.md) | [(5.3)](/filings/0001437749-26-027164.md) |
| Diluted EPS | $ per share | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Basic EPS | $ per share | [(0.69)](/filings/0001437749-24-034048.md) | not reported | [(0.51)](/filings/0001437749-25-016263.md) | [(0.49)](/filings/0001437749-25-026042.md) | [(0.37)](/filings/0001437749-25-034617.md) | not reported | [(0.38)](/filings/0001437749-26-016982.md) | [(0.35)](/filings/0001437749-26-027164.md) | [(0.48)](/filings/0001437749-25-034617.md) | not reported | [(0.46)](/filings/0001437749-26-016982.md) | [(0.62)](/filings/0001437749-26-027164.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: not reported
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [5.5](/filings/0001437749-23-031066.md) | [7.3](/filings/0001437749-25-009979.md) | [7.8](/filings/0001437749-24-015454.md) | [6.1](/filings/0001437749-24-025651.md) | [6.0](/filings/0001437749-24-034048.md) | [45.8](/filings/0001437749-26-010025.md) | [39.7](/filings/0001437749-25-016263.md) | [39.5](/filings/0001437749-25-026042.md) | [128](/filings/0001437749-25-034617.md) | [61.8](/filings/0001437749-26-027164.md) | [52.5](/filings/0001437749-26-016982.md) | [52.8](/filings/0001437749-26-027164.md) |
| Current assets | $m | [8.6](/filings/0001437749-23-031066.md) | [7.3](/filings/0001437749-25-009979.md) | [8.9](/filings/0001437749-24-015454.md) | [7.2](/filings/0001437749-24-025651.md) | [6.1](/filings/0001437749-24-034048.md) | [60.3](/filings/0001437749-26-010025.md) | [55.1](/filings/0001437749-25-016263.md) | [53.7](/filings/0001437749-25-026042.md) | [144](/filings/0001437749-25-034617.md) | [140](/filings/0001437749-26-027164.md) | [138](/filings/0001437749-26-016982.md) | [135](/filings/0001437749-26-027164.md) |
| Total assets | $m | [8.6](/filings/0001437749-23-031066.md) | [7.3](/filings/0001437749-25-009979.md) | [8.9](/filings/0001437749-24-015454.md) | [7.2](/filings/0001437749-24-025651.md) | [6.1](/filings/0001437749-24-034048.md) | [60.3](/filings/0001437749-26-010025.md) | [55.1](/filings/0001437749-25-016263.md) | [53.9](/filings/0001437749-25-026042.md) | [144](/filings/0001437749-25-034617.md) | [141](/filings/0001437749-26-027164.md) | [138](/filings/0001437749-26-016982.md) | [135](/filings/0001437749-26-027164.md) |
| Current liabilities | $m | [2.0](/filings/0001437749-23-031066.md) | [1.8](/filings/0001437749-24-009687.md) | not reported | not reported | not reported | [5.3](/filings/0001437749-26-010025.md) | not reported | [1.6](/filings/0001437749-25-026042.md) | [2.6](/filings/0001437749-25-034617.md) | [2.7](/filings/0001437749-26-027164.md) | [2.5](/filings/0001437749-26-016982.md) | [4.0](/filings/0001437749-26-027164.md) |
| Total liabilities | $m | [2.0](/filings/0001437749-23-031066.md) | [1.8](/filings/0001437749-25-009979.md) | [1.4](/filings/0001437749-24-015454.md) | [1.1](/filings/0001437749-24-025651.md) | [1.1](/filings/0001437749-24-034048.md) | [5.3](/filings/0001437749-26-010025.md) | [1.5](/filings/0001437749-25-016263.md) | [1.7](/filings/0001437749-25-026042.md) | [2.6](/filings/0001437749-25-034617.md) | [2.9](/filings/0001437749-26-027164.md) | [2.6](/filings/0001437749-26-016982.md) | [4.1](/filings/0001437749-26-027164.md) |
| Shareholders' equity | $m | [6.6](/filings/0001437749-24-034048.md) | [5.6](/filings/0001437749-26-010025.md) | [7.5](/filings/0001437749-25-034617.md) | [6.1](/filings/0001437749-25-034617.md) | [4.9](/filings/0001437749-25-034617.md) | [55.0](/filings/0001437749-26-027164.md) | [53.6](/filings/0001437749-26-027164.md) | [52.2](/filings/0001437749-26-027164.md) | [142](/filings/0001437749-25-034617.md) | [138](/filings/0001437749-26-027164.md) | [135](/filings/0001437749-26-027164.md) | [131](/filings/0001437749-26-027164.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,940) d](/filings/0001437749-24-034048.md) | [(1,546) d](/filings/0001437749-25-009979.md) | [(1,655)](/filings/0001437749-25-016263.md) | [(1,677) d](/filings/0001437749-25-026042.md) | [(1,074) d](/filings/0001437749-25-034617.md) | [(1,998) d](/filings/0001437749-26-010025.md) | [(5,663)](/filings/0001437749-26-016982.md) | [(1,077) d](/filings/0001437749-26-027164.md) | [(2,091) d](/filings/0001437749-25-034617.md) | [(3,370) d](/filings/0001437749-26-010025.md) | [(3,474)](/filings/0001437749-26-016982.md) | [(3,247) d](/filings/0001437749-26-027164.md) |
| Share repurchases | $k | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001437749-26-010025.md) | not reported | not reported | not reported | [0.0 d](/filings/0001437749-26-010025.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

Shares outstanding: 6,712,172 at 2026-07-31, from the cover of the [10-Q filed 2026-08-12](/filings/0001437749-26-027164.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.